Clinical Trials Logo

Clinical Trial Summary

Many transplant recipients may experience physical and emotional symptoms, such as anxiety, fatigue, sleep problems, pain, etc. Often, these symptoms are not reported or managed well, and can affect a patient's quality-of-life. Transplant recipients are grateful for the "gift of life" but physical and emotional symptoms reduce their quality-of-life. Transplant recipients and caregivers have felt unprepared for the ongoing symptoms and reduced quality-of-life post-transplant. One way of monitoring and managing these symptoms is using the Emotion And Symptom-focused Engagement (EASE) intervention. EASE was originally developed for patients with acute leukemia and has begun to be adapted to help monitor and manage physical and emotional symptoms for organ transplant recipients. EASE is comprised of two components: 1. Psychological - 8 supportive counselling sessions delivered by mental health clinicians to address concerns about mental health, losses from organ failure, coping with a transplant, experiences with living on the brink of death for a prolonged period of time, etc. 2. Physical - Regular assessments of physical symptoms using questionnaires and referral to healthcare professionals for symptom management as necessary. EASE uses questionnaires, also called patient reported outcome measures (PROMs), for symptom assessment and monitoring. PROMs measure symptom severity, similarly to how bloodwork measures organ functioning. PROMs, as part of EASE, will ask recipients questions and help identify relevant physical, emotional, and social symptoms to enhance their care. With the help of specialists, patients, and support from the Kidney Foundation of Canada, our team has begun to adapt the EASE intervention for transplant recipients. In order to finalize the adaptation of the EASE intervention for use in a routine transplant clinic, we are launching a pre-pilot study to gain real-life experience from managing symptoms of SOT recipients with the use of EASE-SOT.


Clinical Trial Description

This is a parallel arm, randomized, controlled pilot study that will assess the feasibility for a large effectiveness trial using the EASE intervention to screen and manage emotional distress and physical symptoms among solid organ transplant (SOT) recipients. We will use a sequential cluster organization for recruitment. Initially, we will recruit kidney and kidney-pancreas transplant recipients, since we already have funding for this portion of our work. Subsequently, we will complete our study plan by recruiting liver, lung, and heart transplant recipients. EASE integrates supportive counseling and trauma-focused cognitive behavioral therapy (CBT) (EASE-psy) with systematic physical symptom screening and triggered referral to supportive care to manage moderate to severe physical symptoms (EASE-phys). Participants in the intervention group receive EASE plus usual care. Each participant will participate in 8 EASE-psy sessions, starting twice a week during the inpatient stay and once every 1-2 week thereafter. They will also be screened for physical symptoms using electronic patient-reported outcome measures (ePROMs) twice a week while in-patient and once a week during the rest of the 8-week intervention period (EASE-phys). Based on individual preference, participants will receive these ePROMs either on tablets or their personal electronic devices via email, while in the hospital ward or in clinics, ensuring easy access and administration of these tools. Participants will receive an output report that provides graphic representation of their current and previous scores on the various domains of health (e.g., depression, fatigue, etc.). This report will contain customized embedded URL links to the Symptomcare public domain. Embedded links will be in the form of: https://symptomcare.org/managing-my-symptoms-overview-patient/depression/?subjectid=1234&toke n=abcd. If scoring above threshold for any symptom assessed during routine screening, participants will be referred/re-referred to a "symptom control" team. Participants in the control group receive usual care alone. Additional ePROMs will be completed at baseline, 4, 8 12 and 20 weeks by patients in both arms. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06396702
Study type Interventional
Source University Health Network, Toronto
Contact Istvan Mucsi
Phone 4166596756
Email istvan.mucsi@utoronto.ca
Status Not yet recruiting
Phase N/A
Start date May 2024
Completion date August 2027

See also
  Status Clinical Trial Phase
Withdrawn NCT05811468 - Study Correlation Between Blood, Tissue Gene Expression, Donor Derived Cell Free DNA and Histopathology in Kidney Transplant Recipients
Active, not recruiting NCT04166149 - Eliminating the Need for Pancreas Biopsy Using Peripheral Blood Cell-free DNA
Completed NCT03723668 - Kidney Transplant Outcome and Organ Acceptance Practice Pattern: A Nationwide Analyses in the US and France
Recruiting NCT03737604 - TAP Blocks With Ropivacaine Continuous Infusion Catheters vs Single Dose Liposomal Bupivicaine After Kidney Transplant Phase 4
Completed NCT03765203 - Utility of a Novel Dd-cfDNA Test to Detect Injury in Renal Post-Transplant Patients N/A
Completed NCT05809440 - Effectiveness of 20m-MB in KTR Symptom Control N/A
Enrolling by invitation NCT04491227 - Global Assessment of Acute and Chronic Kidney Disease Incidence and Outcomes in Patients With COVID-19 Infection
Recruiting NCT03310905 - Abdominal Wall Transplant N/A
Recruiting NCT05613010 - Leveraging Technology to Improve Medication Adherence in Youth With Kidney or Liver Transplant N/A
Recruiting NCT06263257 - The Effect of Mandala Therapy on Anxiety and Comfort in Kidney Transplant Recipients N/A
Completed NCT04715412 - Clinical Pharmacy Guided Patient Counselling and Adherence Support on Renal Transplant Recipients N/A
Active, not recruiting NCT05449496 - Dietary Intervention to Improve Kidney Transplant Outcomes N/A
Not yet recruiting NCT06089473 - Virtual Home-based Physical Pre-habilitation in Kidney Transplant Candidates N/A
Withdrawn NCT04473924 - Standard Therapy or Individualized Immunosuppression For Lowering Adverse Event Risk Phase 2
Recruiting NCT04619732 - Real-time Monitoring of Kidney Grafts on Hypothermic Machine Perfusion N/A
Completed NCT03760263 - Evaluation Dose Adjustments in Kidney Transplant Patients on Immediate Release and Extended Release Tacrolimus Phase 4
Active, not recruiting NCT03380962 - Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant Phase 1/Phase 2
Active, not recruiting NCT03436368 - Continuous Spinal Anesthesia in Renal Transplantation N/A
Not yet recruiting NCT03322709 - Minimally Invasive Kidney Transplantation N/A
Recruiting NCT03778944 - Enhancing Renal Graft Function During Donor Anesthesia N/A